RecruitingNCT02206841

Establishment of NAFLD Cohort and Development of Fibrosis Markers

Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis

Sponsor

Seoul National University Boramae Hospital

Enrollment

1,000 participants

Start Date

Jan 1, 2014

Study Type

OBSERVATIONAL

Conditions

Fibrosis of Liver

Summary

This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called ARFI, a procedure called Liver biopsy, and others for people with fibrosis of liver. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELiver biopsy

Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.

DEVICEARFI

Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.

DEVICESWE

Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.

DEVICETransient elastography

Transient elastography will be performed for evaluate fibrosis of liver.

Locations(1)

Seoul Metropolitan Government Seoul National University

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02206841

Related Trials

Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers

NCT073597421 location